GC
RYTM icon

Grace Capital’s Rhythm Pharmaceuticals RYTM Stock Holding History

Grace Capital’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-554
Closed -$16K – 246
2020
Q4 		$16K Hold
554
– – 0.01% 245
2020
Q3 		$12K Hold
554
– – 0.01% 229
2020
Q2 		$12K Hold
554
– – 0.01% 207
2020
Q1 		$8K Hold
554
– – 0.01% 177
2019
Q4 		$13K Buy
+554
New +$12.3K 0.01% 190

Other funds holding RYTM

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Grace Capital's RYTM Position: Q1 2021 in Review

Grace Capital sold out of Rhythm Pharmaceuticals (RYTM) in Q1 2021, closing a stake of 554 shares — an estimated $16K sold.

Grace Capital first reported a position in RYTM in Q4 2019 and held it in 5 quarters. The position peaked at $16K in Q4 2020. 124 funds tracked by Wall St. Rank hold RYTM as of Q1 2021.

  • Grace Capital reported no remaining Rhythm Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Grace Capital sold 554 Rhythm Pharmaceuticals shares in Q1 2021, an estimated $16K.
  • Grace Capital first reported a position in Rhythm Pharmaceuticals in Q4 2019 and held it in 5 quarters.
  • Grace Capital's Rhythm Pharmaceuticals position peaked at $16K in Q4 2020.
  • 124 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2021.

Based on Grace Capital's 13F filing for Q1 2021, filed 6 May 2021.